Can NSAIDs contribute to Alzheimer's disease?

Secko, David
June 2005
CMAJ: Canadian Medical Association Journal;6/21/2005, Vol. 172 Issue 13, p1677
Academic Journal
Presents the results of a study regarding the determination of nonsteroidal anti-inflammatory drugs (NSAID) which decreased the production of amyloid beta-protein peptide. Types of NSAID that decrease amyloid beta-protein peptide with 42 amino acids in cells; Cyclooxygenase-2 inhibitors which increase the production of amyloid beta-protein peptide; Clinical implications of the results to the design of drugs the inhibit the production of amyloid beta-proteins.


Related Articles

  • Killing pain, killing neurons? Wyss-Coray, Tony // Nature Medicine;May2005, Vol. 11 Issue 5, p472 

    Discusses studies suggesting that some COX-2 inhibitors may actually promote the production of amyloid-?, a toxic peptide thought to have a major role in Alzheimer disease. Negative outcome of placebo-controlled clinical treatment trials of the efficacy of nonsteroidal anti-inflammatory drugs...

  • Dynamic Simulations on the Arachidonic Acid Metabolic Network. Kun Yang; Wenzhe Ma; Huanhuan Liang; Qi Ouyang; Chao Tang; Luhua Lai // PLoS Computational Biology;Mar2007, Vol. 3 Issue 3, p0523 

    Drug molecules not only interact with specific targets, but also alter the state and function of the associated biological network. How to design drugs and evaluate their functions at the systems level becomes a key issue in highly efficient and low-side-effect drug design. The arachidonic acid...

  • Newer Arthritis Drugs Don't Offer Anti-Bleeding Protection For Everyone.  // Tufts University Health & Nutrition Letter;Feb2003, Vol. 20 Issue 12, p6 

    Presents a study that showed the risks of taking nonsteroidal anti-inflammatories such as Cox-2 inhibitors.

  • Docking studies on NSAID/COX-2 isozyme complexes using Contact Statistics analysis. Ermondi, Giuseppe; Caron, Giulia; Lawrence, Raelene; Longo, Dario // Journal of Computer-Aided Molecular Design;Nov2004, Vol. 18 Issue 11, p683 

    The selective inhibition of COX-2 isozymes should lead to a new generation of NSAIDs with significantly reduced side effects; e.g. celecoxib (Celebrex�) and rofecoxib (Vioxx�). To obtain inhibitors with higher selectivity it has become essential to gain additional insight into the...

  • Coxibs not always cost-effective for treating chronic arthritis.  // Formulary;Aug2003, Vol. 38 Issue 8, p459 

    Reports that cyclooxygenase-2 selective inhibitors (coxibs) may not be cost-effective for the treatment of chronic arthritis pain in patients at average risk for ulcer complications. Comparison of coxibs with nonselective nonsteroidal anti-inflammatory drugs; Risk reduction average of coxibs.

  • Renal effects of cyclooxygenase inhibitors in volume-depleted dogs. Brooks, David P.; Adams, Jerry; DePalma, P. Dennis; Webb, Edward F.; Palmer, Robert H.; Griswold, Don E. // Inflammopharmacology;2000, Vol. 8 Issue 1, p69 

    Objective: The objective of this study was to investigate the renal effects of celecoxib, a cyclooxygenase-2 (COX-2) specific nonsteroidal anti-inflammatory drug (NSAID). Subjects and treatment: Six volume-depleted, conscious, chronically instrumented dogs received four treatments using a...

  • Celecoxib and rofecoxib. Moore, Paul A.; Hersh, Elliot V. // Journal of the American Dental Association (JADA);Apr2001, Vol. 132 Issue 4, p451 

    Reports on the development of the nonsteroidal anti-inflammatory drugs (NSAID), celecoxib and rofecoxib, to limit the adverse effects seen after chronic use of NSAID. Cyclo-oxygenase mechanism; Specific cyclo-oxygenase 2 inhibitors; Decrease in the antihypertensive effects of...

  • Review of the selective COX-2 inhibitors celecoxib and rofecoxib: focus on clinical aspects. Loewen, Peter S. // CJEM: Canadian Journal of Emergency Medicine;Jul2002, Vol. 4 Issue 4, p268 

    Discusses the efficacy and safety data available for celecoxib and rofecoxib, emphasizing comparisons between cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory drugs. Effectiveness of the drugs in treating osteoarthritis, rheumatoid arthritis, postoperative dental pain and...

  • NSAIDs: the Emperor's new dogma? Bjarnason I; Takeuchi K; Simpson R // Gut;Sep2003, Vol. 52 Issue 9, p1376 

    The spectacular marketing success of the selective cyclooxygenase 2 (COX-2) inhibitors is largely based on efficacy comparable with conventional non-steroidal anti-inflammatory drugs (NSAIDs) with vastly improved gastrointestinal safety. The additional key to the marketing success is the purity...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics